Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-302 with Chemoradiotherapy in Esophageal Cancer
NCT02598687Phase 1Withdrawn
- Sponsor
- Maastro Clinic
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of evofosfamide in esophageal adenocarcinoma (EAC) and esophagogastric junction adenocarcinoma (GEJA), sponsored by Maastro Clinic. Primary endpoint: Dose Limiting Toxicity. Planned start Dec 2015; status: withdrawn.
02
Drugs
evofosfamide
03
Conditions
esophageal adenocarcinoma (EAC)esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT02598687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598687.